Can nomograms be superior to other prediction tools?
|
|
- Gregory Barber
- 5 years ago
- Views:
Transcription
1 . JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology NOMOGRAMS ARE SUPERIOR TO OTHER CURRENT PREDICTION TOOLS SHARIAT et al. BJUI BJU INTERNATIONAL Can nomograms be superior to other prediction tools? Shahrokh F. Shariat, Umberto Capitanio*, Claudio Jeldres and Pierre I. Karakiewicz Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, *Department of Urology, Vita- Salute San Raffaele, Milan, Italy, and Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada Accepted for publication 18 June 2008 Accurate estimates of the likelihood of treatment success, complications and longterm morbidity are essential for counselling and informed decision-making in patients with urological malignancies. Accurate risk estimates are also required for clinical trial design, to ensure homogeneous patient distribution. Nomograms, risk groupings, artificial neural networks (ANNs), probability tables, and classification and regression tree (CART) analyses represent the available decision aids that can be used within these tasks. We critically reviewed available decision aids (nomograms, risk groupings, ANNs, probability tables and CART analyses) and compared their ability to predict the outcome of interest. Of the available decision aids, nomograms provide individualized evidence-based and highly accurate risk estimates that facilitate management-related decisions. We suggest the use of nomograms for the purpose of evidence-based, individualized decisionmaking. KEYWORDS nomograms, artificial neural networks, risk groupings, probability tables, classification and regression trees INTRODUCTION Accurate estimates of the likelihood of treatment success, complications and longterm morbidity are essential for counselling and informed decision-making in patients with urological malignancies. Informed consent that is based on accurate estimation of the likelihood of various treatment outcomes might improve treatment satisfaction, particularly when complications arise [1]. Accurate risk estimates are also required for clinical trial design, to ensure an homogeneous distribution of risk factors across trial arms. There are several options for risk estimation in medicine, including urological oncology. In the complete absence of data, physicians can refuse to even attempt to make valid predictions. This might be the case with extremely rare pathologies. Alternatively, predictions can be made based on personal knowledge and experience. This method is frequently used in clinical practice, where clinicians rely on a mix of objective and subjective experience [2,3]. Quoting an average outcome probability represents another option. The use of data from randomized clinical trials (RCTs) can illustrate this situation. For example, based on the report by Bill-Axelson et al. [4] of an RCT of radical prostatectomy (RP) vs watchful waiting, a 60-year-old patient could be told that relative to watchful waiting, RP will decrease his risk of death from prostate cancer by virtually 50%, from 20% to 10%, at 10 years of follow-up. Although such data are based on high-quality evidence, they do not appeal universally to patients or clinicians. The reluctance to use RCT data stems from the patients and clinicians awareness that differences in individual patient characteristics might undermine the validity of such results in individual cases. Based on this limitation, various predictive models have been proposed [3,5]. In this review we provide a systematic approach allowing an assessment of the strengths and the weakness of available models. KATTAN-TYPE NOMOGRAMS The statistical definition of a nomogram is a graphical representation of a mathematical formula. The predictors of such a formula might be modelled as continuous or categorical variables to predict a particular endpoint. The statistical methods can consist of multivariable logistic regression or Cox proportional hazards analyses [6]. Nomograms consist of several axes; each variable is represented by a scale, with each value of that variable corresponding to a specific number of points according to its prognostic significance. For example, the nomogram in Fig. 1 [6] assigns to each PSA level a unique point value that represents its prognostic significance. In a final pair of axes, the total point value from all the variables is converted to the probability of reaching the endpoint of interest. Nomograms provide the probability of a particular outcome on a continuous scale, which is usually 0 100%. DECISION-TOOL REQUIREMENTS The discriminant properties (ability to predict the outcome of interest) of nomograms and other decision tools is measured using the concordance index (or c-index), which is virtually synonymous with the area under the receiver operating characteristic curve. While the area under the curve requires binary outcomes (e.g. cure/fail), the c-index can be applied in the presence of case censoring and is used in analyses of time-to-event data [7]. In such analyses, the c-index indicates how accurate the model predictions are. A model with 50% concordance is as good as the toss of a coin. The c-index of most models is 70 85%; few models exceed 80% accuracy 492 JOURNAL COMPILATION 2008 BJU INTERNATIONAL 103, doi: /j x x
2 NOMOGRAMS ARE SUPERIOR TO OTHER CURRENT PREDICTION TOOLS FIG. 1. A preoperative nomogram based on 983 patients treated at The Methodist Hospital, Houston, TX, for predicting PSA recurrence after RP [6]. Preoperative Nomogram for Prostate Cancer Recurrence Points PSA Clinical Stage Biopsy Gleason Sum T2a T2c T3a T1c T1ab T2b * Total Points Month Rec. Free Prob (concordance). Concordance provides an overall measure of a model s ability to discriminate between individuals with and without the endpoint of interest. A model might predict very well in low-risk patients; conversely, it might predict extremely poorly in high-risk individuals. If the proportion of low-risk individuals is high relative to highrisk individuals, the overall accuracy might be very good and the c-index might not alert the potential model user to its deficiencies when high-risk patients are assessed. Model calibration circumvents this limitation of the c-index calibration plots that graphically depict the model s calibration, and should always accompany c-index-derived accuracy estimates. Calibration plots show the model s predicted probability on the x-axis and the observed rate of the event of interest on the y-axis. Perfect calibration is achieved when predicted probabilities match the observed rate as 1:1. A 45 line is indicative of a perfect calibration. Most good models will show minor departures from ideal predictions, manifested by underestimation of the observed rate (calibration curve above the ideal 45 line) or by overestimation of the observed rate (calibration curve below the ideal 45 line). Both metrics, discrimination and calibration, should be reported with each model. The provision of just one of these two metrics is insufficient to warrant the implementation of a model into clinical practice. Moreover, both metrics should ideally be applied to an external validation sample, which is needed to ultimately confirm the performance characteristics of a model. Unfortunately, external data might not always be available. Under such circumstance it is imperative to perform an internal validation, where bootstrapping simulates the application of the model under novel testing conditions. Other forms of internal validation, such as cross-validation or data splitting, are less efficient and provide substantially more biased estimates of model s true accuracy. Failure to subject a model to external or internal validation tests might result in spuriously elevated accuracy. Taken together, three criteria are required to assess a predictive or prognostic model: (i) the presence of an internal or external validation; (ii) a measure of accuracy (discrimination); and (iii) an assessment of the model s calibration. COMPARISON OF NOMOGRAMS WITH OTHER PREDICTION TOOLS NOMOGRAM VS RISK GROUPINGS Physicians often use risk groups to predict the treated natural history of the disease. Patients with similar characteristics are aggregated in risk strata such as high, intermediate or low. Despite its apparent logic, this method is statistically inefficient and might reduce the accuracy. Its flaws consists of the assumption that all patients within a risk group are equal, but risk groups might be heterogeneous. A commonly used risk-grouping tool was developed by D Amico et al. [8,9] for predicting biochemical recurrence in patients treated with RP, external-beam radiotherapy or brachytherapy. It places patients into mutually exclusive risk groups based on clinical stage, biopsy Gleason sum and pretreatment PSA level. Various studies have documented the superior performance of nomograms compared to risk-grouping [10 12]. This might stem from intergroup heterogeneity or from the effect of spectrum bias that reduces the influence of significantly lower or higher values than those observed for most patients. By contrast to risk groups, nomograms rely on the most informative type of data coding. For example, continuously risk-coded values will not be categorized, to avoid spectrum bias and heterogeneity within strata. NOMOGRAM VS LOOK-UP TABLES The superior predictive accuracy of multivariable nomograms vs look-up tables is illustrated in a comparison of a nomogram to the Partin Tables [13,14], to predict the pathological features of prostate cancer, with a suite of nomograms. The Partin tables combine serum PSA level (four categories), clinical stage (seven categories), and biopsy Gleason sum (five categories) to predict organconfined, established extracapsular extension, seminal vesicle invasion, and lymph node involvement at RP. Several studies compared the Partin tables with nomograms predicting the same endpoints, and showed that nomograms had superior accuracy in predicting organ-confined disease, seminal vesicle invasion and lymph node invasion [10,15]. The differences in accuracy might not be trivial; Chun et al. [16] showed that a logistic regression-based nomogram predicting Gleason sum upgrading was 80.4% accurate, vs 52.3% accuracy for a look-up table (P < 0.001). Moreover, the nomogram showed virtually ideal performance. Conversely, important departures from an ideal prediction were recorded for the look-up table. This said, a formal external validation of the Chun et al. nomogram is pending; this comparison will provide ultimate and validated proof of the accuracy of this model. Until then, the advantage of the nomogram over the look-up table will rest on a comparison between external and internal validation, that provides an advantage to the nomogram format. NOMOGRAM VS TREE ANALYSIS Classification and regression tree (CART) analysis is another type of predictive model that uses nonparametric techniques to evaluate data, account for complex relationships, and present the results in a clinically useful form. CARTs rely on progressive splitting of the population (Fig. 2). Splits are based on considerations of statistical significance. The variables that are chosen for each split, the discriminatory values, and the order in which the splitting occurs are all produced by the underlying mathematical algorithms that maximize the model s discriminant ability. This type of approach can inflate type I error, as it relies heavily on data-based associations. In such cases internal or external validation is particularly important [17]. As for look-up tables, CART analyses are limited by variable coding limitations, as only categories are allowed. This results in intergroup heterogeneity and in spectrum JOURNAL COMPILATION 2008 BJU INTERNATIONAL 493
3 SHARIAT ET AL. bias. Several studies have shown that traditional statistical methods perform better than CART analysis. Kattan et al. [10] showed that Cox proportional hazards regression models provided superior predictive accuracy than four tree-based methods. Artificial neural networks (ANNs) are also not bound by the CART boundaries and offer an advantage. Chun et al. [11] showed that a logistic regression-based nomogram was superior to a CART model for predicting the side of extracapsular extension (84% vs 70%). Moreover, the nomogram calibration plot was substantially better than that of the CART model. NOMOGRAM VS ANNS In the last 10 years a new class of techniques, the ANN, has been proposed as a supplement or alternative to standard statistical techniques. An ANN classifies a patient s cancer risk through a complex learning process, where data are manipulated in system layers of hidden software neurones (Fig. 3). The data are divided into three parts; the training set, the validation (or testing) set and the verification set. The sample sizes of the sets can be variable. In general, the sample sizes depend on the number of predictions, the homogeneity of patient characteristics, the distribution of prediction, and the strength of the association between predictors and the outcome. The network is then presented with the training set, which provides inputs (one or many risk factors) and desired output (e.g. the presence or absence of prostate cancer). The network then assigns weights and interactions to input variables to promote self-learning and to maximize discriminant ability. The validation set is used to decide when to stop training the network and the verification set is used to report the performance of the ANN. The validation set is not synonymous with an internal or external validation of a nomogram. Theoretically, an ANN should have considerable advantages over standard statistical approaches, as there are no rules for variable coding or interactions. This represents an advantage over standard statistical models, which at most can account for one or two interactions. Additionally, ANNs do not require explicit distributional assumptions (such as normality). However, ANNs are not without their drawbacks. The primary disadvantage of an ANN is its black box quality. It is impossible to detect internal modelling flaws within an ANN model. Despite the significant and often fruitful efforts aimed at opening the black box, several practical disadvantages of the ANN persist. For example, sequential modelreduction techniques, such as the Akaike criteria, allow stepwise and user-defined removal of variables of lesser significance in regression models. Individual regression coefficients and their significance, which indicate the magnitude, direction and importance of each variable, cannot be examined. Based on these considerations, in a review of 28 studies comparing ANN and regression modelling, it was concluded that regressionbased techniques are similar to ANNs in several characteristics. They offer an alternative method, and the performance and accuracy can be equal to regression-based models, especially if the sample size is large [18]. In a literature review, Schwarzer et al. [19] concluded that machine-learning methods have often failed to perform better than traditional statistical methods, and they outlined numerous design flaws in studies that suggested the superiority of ANNs. For example, in several analyses the investigators failed to test the ANN using a verification dataset, which is equivalent to assessing the discriminant properties of a regression model without accounting for the effect of overfit bias, that is accounted for by either internal or external validation. Several authors directly compared ANNs and regression-based models; Terrin et al. [20], Kattan et al. [10] and Chun et al. [21] found that regression models outperformed ANNs when both methods were subjected to formal external validations with equally strict testing criteria. However, others did not confirm this, first in a large review on 72 studies comparing ANN and regression, where in 51% ANN was better than regression, with no difference of ANN and regression in 42% [22], and second in the same tested population [23] as used by Chun et al. [21]. CONCLUSIONS The use of prognostic and decision aids in urology, e.g. nomograms, look-up tables, risk grouping, CART analysis, and ANNs, has grown rapidly in the last decade. Most such FIG. 2. A simplified example of a CART-recursive partitioning based on a logistic regression analyses. In this analysis, the clinician simply follows the paths of the tree that describes the characteristics of the patient being evaluated, and arrives at the prediction of the outcome of interest for that particular patient. 1 biopsy with Gleason 4/5 PCa PSA < 1ng/ml 1 predicted OC-PCa probability: 86% all prostate lobes PSA 1ng/ml 1 probability biopsy Predicted OC-PCa probability: 72% >1 biopsy with Gleason 4/5 PCa Predicted OC-PCa probability: 22% >1 positive biopsy Predicted OC-PCa probability: 45% FIG. 3. Example of the interconnections of an ANN (prostate cancer biopsy). Predictive covariates Input nodes Hidden nodes Output node PSA Ratio PSA Complex PSA Age Prostate Volume PSA Density PSA Velocity Diet Race General Health 1 = YES 2 = NO tools provide accurate risk estimation and potentially complement clinical judgement. Continuous multivariable models such as nomograms have consistently shown better performance characteristics than the other options. Moreover, nomograms provide a user-friendly interface, which does not require computer software for interpretation/ prediction. Nonetheless, virtually all available nomograms are accessible in either webbased or in palm-top computer formats for those interested in electronic application ( and In the future, the predictive ability of nomograms might be improved by incorporating biological markers of disease, quality-of-life measures, or applying prognostic modelling to individual physician 494 JOURNAL COMPILATION 2008 BJU INTERNATIONAL
4 NOMOGRAMS ARE SUPERIOR TO OTHER CURRENT PREDICTION TOOLS or group datasets. At present, nomograms allow clinicians to standardize clinical decision-making using evidence-based and fully individualized tools. Most importantly, nomograms provide accurate and reproducible predictions for patients, who deserve the most accurate prediction of their disease characteristics. CONFLICT OF INTEREST None declared. REFERENCES 1 Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001; 19: Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000; 164: Ross PL, Gerigk C, Gonen M et al. Comparisons of nomograms and urologists predictions in prostate cancer. Semin Urol Oncol 2002; 20: Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001; 165: Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: Begg CB, Cramer LD, Venkatraman ES, Rosai J. Comparing tumour staging and grading systems: a case study and a review of the issues, using thymoma as a model. Stat Med 2000; 19: D Amico AV, Whittington R, Malkowicz SB et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000; 55: D Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostatespecific antigen era. J Clin Oncol 2003; 21: Kattan MW. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol 2003; 170: S Chun FK, Karakiewicz PI, Briganti A et al. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 2007; 99: Ponzone R, Maggiorotto F, Mariani L et al. Comparison of two models for the prediction of nonsentinel node metastases in breast cancer. Am J Surg 2007; 193: Makarov DV, Trock BJ, Humphreys EB et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to Urology 2007; 69: Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: Gallina A, Chun FK, Briganti A et al. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur Urol 2007; 52: Chun FK, Steuber T, Erbersdobler A et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006; 49: Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 2000; 19: Sargent DJ. Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer 2001; 91: Schwarzer G, Schumacher M. Artificial neural networks for diagnosis and prognosis in prostate cancer. Semin Urol Oncol 2002; 20: Terrin N, Schmid CH, Griffith JL, D Agostino RB, Selker HP. External validity of predictive models: a comparison of logistic regression, classification trees, and neural networks. J Clin Epidemiol 2003; 56: Chun FK, Graefen M, Briganti A et al. Initial biopsy outcome prediction head-to-head comparison of a logistic 51: Dreiseitl S, Ohno-Machado L. Logistic regression and artificial neural network classification models: a methodology review. J Biomed Inform 2002; 35: Stephan C, Meyer HA, Cammann H et al. Initial biopsy outcome prediction head-to-head comparison of a logistic 51: Correspondence: Shahrokh F. Shariat, Department of Urology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX , USA. sfshariat@gmail.com or shariats@mskcc.org Abbreviations: RCT, randomized clinical trial; RP, radical prostatectomy; c-index, concordance index; CART, classification and regression tree; ANN, artificial neural network. EDITORIAL COMMENT Shariat et al. reviewed different multivariate models for the diagnosis and staging of prostate cancer, and recommended nomograms as tools for decision-making. We agree that logistic regression (LR)-based nomograms have several advantages over risk groupings, look-up tables or CART analysis. However, there were several studies not considered in their review [1 3], which could not confirm a better performance of LR-based models compared with ANNs. The example of the highly praised study by Chun et al. [4], where the advantage of the nomogram disappears when simply considering the different PSA assays [5] shows that many factors such as analytical, computational and, most importantly, population-based JOURNAL COMPILATION 2008 BJU INTERNATIONAL 495
5 SHARIAT ET AL. differences must be considered before one can state that LR-based nomograms are superior to ANNs, as unfortunately done in the past [6,7]. From the mathematical point of view it would be surprising if LR-based models outweigh ANN models which can more easily handle complex biological systems. An important review found no differences in 28 studies comparing both LR and ANN, especially when the number of patients is large [8]. ANN and LR models both clearly have an over single variables. It is not the question of which models perform somewhat better, but how to convince physicians that multivariable models work better than one marker alone, e.g. %free PSA or total PSA. Carsten Stephan*, Henning Cammann and Klaus Jung* *Department of Urology and Institute of Medical Informatics, Charité Universitätsmedizin Berlin, and Berlin Institute for Urological Research, Berlin, Germany REFERENCES 1 Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002; 20: Finne P, Finne R, Auvinen A et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000; 56: Kalra P, Togami J, Bansal BS et al. A neurocomputational model for prostate carcinoma detection. Cancer 2003; 98: Chun FK, Graefen M, Briganti A et al. Initial biopsy outcome prediction head-to-head comparison of a logistic 51: Stephan C, Meyer HA, Cammann H, Lein M, Loening SA, Jung K. Re Initial biopsy outcome prediction head-tohead comparison of a logistic 51: Chun FK, Karakiewicz PI, Briganti A et al. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 2007; 99: Karakiewicz PI, Chun FK, Briganti A et al. Prostate cancer nomograms are superior to neural networks. Can J Urol 2006; 13 (Suppl. 2): Sargent DJ. Comparison of artificial neural networks with other statistical approaches. Cancer 2001; 91: REPLY We agree with the comments of Stephan et al. that the modelling type matters little, while the ability to predict with accuracy matters the most. This said, it is not surprising that various modelling techniques that are based on data-driven relationships might outperform one another. For example, a nomogram based on cubic splines (datadriven) can be as powerful in predicting the outcome of interest as are ANNs. Although it might be of interest to some to debate which model is most accurate, once the maximum accuracy has been reached and it is not 100% perfect, some clinicians might reject the option of model-derived predictions. For now, no model in urological oncology can provide 100% accurate predictions. Residual sources of error account for a misclassification rate of 15 25%, when for example biochemical recurrence (BCR) or other endpoints are examined. Should this error rate discourage clinicians from relying on multivariable predictor and prognostic tools? The answer is definitely not. Although predictive and prognostic tools are not perfect, their ability to foretell the outcome of interest exceeds that of expert clinicians substantially and statistically significantly. For example, clinician experts at Memorial Sloan-Kettering Cancer Center were 54% accurate in predicting lymph node metastases, vs 72% for nomogram-based predictions [1]. Similarly, clinicians were, on average, 68% accurate in predicting the life-expectancy of patients with prostate cancer treated with either RP or radiotherapy, vs 84.3% for a nomogram predicting the same outcome [2,3]. Of various predictive models, nomograms recently emerged as the preferred format when the opinions of North American urologists were polled [4]. Despite the established benefit of various multivariable models in predicting BCR and other prostate cancer endpoints, scepticism might be encountered when their implementation into routine clinical practice is suggested. Lack of a prospectively confirmed benefit in patient outcomes is commonly used as an argument against the use of predictive and prognostic models. At first glance, clinicians who are accustomed to randomized prospective trials that quantify the benefits and detriments of a standard of care to that of a novel molecule tend to agree with absence of data supporting the usefulness of nomograms in clinical practice. However, a randomized prospective evaluation of nomogram-based decisionmaking vs standard-of-care (clinician-based) decision-making is neither practically nor ethically possible. First, ethical considerations would not allow the randomization of patients to management that is purely based on information technology. Second, nomograms and other predictive or prognostic tools are merely meant to assist the clinician in decision-making. In that regard, they provide the clinician with a probability of a given endpoint, say BCR. When the nomogram states that the patient is 80% likely to have BCR after RP, the clinician might, for example, decide to (i) do nothing, (ii) increase the frequency of follow-up, (iii) initiate adjuvant radiotherapy, or (iv) start androgen deprivation. Although the nomogram-derived prediction of elevated risk of BCR prompts the clinician to select one of the four treatment options, it entirely depends on the clinician s preference which of the choices is selected. It is therefore impossible to objectively test the effect of nomograms on health outcomes, as clinicians choices remain the decisive factors in diagnostic and/or therapeutic decision making. Pierre I. Karakiewicz*, Umberto Capitanio #, Hendrik Isbarn*, Claudio Jeldres* and Shahrokh S. Shariat *Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada; # Department of Urology, Vita-Salute San Raffaele, Milan, Italy; Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA 496 JOURNAL COMPILATION 2008 BJU INTERNATIONAL
6 NOMOGRAMS ARE SUPERIOR TO OTHER CURRENT PREDICTION TOOLS REFERENCES 1 Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005; 12: Walz J, Gallina A, Perrotte P et al. Clinicians are poor raters of lifeexpectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 2007; 100: Walz J, Gallina A, Saad F et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007; 25: Capitanio U, Jeldres C, Shariat SF, Karakiewicz P. Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. Eur Urol 2008; doi: /j.eururo JOURNAL COMPILATION 2008 BJU INTERNATIONAL 497
Predictive Models. Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute
Predictive Models Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute Treatment for clinically localized prostate cancer Trade off: Substantial
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationZonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy
european urology 51 (2007) 949 955 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical
More informationNomograms for prostate cancer
Review Article NOMOGRAMS FOR PROSTATE CANCER STEPHENSON and KATTAN There are several papers in this section on various aspects of prostate cancer: predictive models, robotic radical prostatectomy in large
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationResearch Article External Validation of an Artificial Neural Network and Two Nomograms for Prostate Cancer Detection
International Scholarly Research Network ISRN Urology Volume 2012, Article ID 643181, 6 pages doi:10.5402/2012/643181 Research Article External Validation of an Artificial Neural Network and Two Nomograms
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationeuropean urology 52 (2007)
european urology 52 (2007) 733 745 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Systematic Assessment of the Ability of the Number and Percentage of Positive
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More information1. Introduction. Department of Urology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba , Japan 2
Hindawi Publishing Corporation Prostate Cancer Volume 2011, Article ID 754382, 6 pages doi:10.1155/2011/754382 Clinical Study Development and External Validation of a Nomogram Predicting the Probability
More informationEUROPEAN UROLOGY 61 (2012)
EUROPEAN UROLOGY 61 (2012) 480 487 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by A. Heidenreich on pp. 488 490 of this issue
More informationTHE MOST COMMON definitive therapy for the treatment
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer Michael W. Kattan, Thomas M. Wheeler, and Peter T. Scardino Purpose: Although models exist that place patients
More informationProstate-specific antigen density as a parameter for the prediction of positive lymph nodes at radical prostatectomy
1 di 10 26/12/2015 17.15 Urol Ann. 2015 Oct-Dec; 7(4): 433 437. doi: 10.4103/0974-7796.152118 PMCID: PMC4660691 Prostate-specific antigen density as a parameter for the prediction of positive lymph nodes
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationKey words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationActive Surveillance (AS) is an expectant management. Health Services Research
Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer Health Services Research Jianyu Liu, Paul R. Womble, Selin Merdan, David C. Miller, James E. Montie, Brian T. Denton on
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationHigh Incidence of Prostate Cancer Detected by Saturation Biopsy after Previous Negative Biopsy Series
european urology 50 (2006) 498 505 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer High Incidence of Prostate Cancer Detected by Saturation Biopsy after Previous
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationVictor H. W. Yeung, Yi Chiu, Sylvia S. Y. Yu, W. H. Au, and Steve W. H. Chan
The Scientific World Journal Volume 23, Article ID 5662, 4 pages http://dx.doi.org/.55/23/5662 Clinical Study Are Preoperative Kattan and Stephenson Nomograms Predicting Biochemical Recurrence after Radical
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,
More informationTable 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups
Oncology Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort Umberto Capitanio, Paul Perrotte, Laurent Zini, Nazareno Suardi, Elie Antebi,
More informationMachine Learning for Survival Analysis: A Case Study on Recurrence of Prostate Cancer
Machine Learning for Survival Analysis: A Case Study on Recurrence of Prostate Cancer Blaž Zupan 1,2,4,JanezDemšar 1, Michael W. Kattan 3, J. Robert Beck 4,and I. Bratko 1,2 1 Faculty of Computer Science,
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationUsing Artificial Neural Network to Predict Mortality of Radical Cystectomy for Bladder Cancer
SMARTCOMP 2014 Using Artificial Neural Network to Predict Mortality of Radical Cystectomy for Bladder Cancer Kin-Man Lam Department of Surgery, Tseung Kwan O Hospital New Territories, Hong Kong, China
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationDepartment of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.321 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.321&domain=pdf&date_stamp=2014-05-16
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 24 AUGUST 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T A Nomogram Predicting 10-Year Life Expectancy in Candidates for Radical Prostatectomy or Radiotherapy for Prostate
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationAre Clinically Insignificant Prostate Cancers Really Insignificant among Korean Men?
Original Article http://dx.doi.org/10.3349/ymj.2012.53.2.358 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 53(2):358-362, 2012 Are Clinically Insignificant Prostate Cancers Really Insignificant among
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationBJUI. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis
BJUI BJU INTERNATIONAL Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis Ruslan Korets, Catherine M. Seager, Max S. Pitman, Gregory W. Hruby, Mitchell C. Benson and
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationProstate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram
EUROPEAN UROLOGY 56 (2009) 659 668 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel
More informationNomograms for Bladder Cancer
european urology 54 (2008) 41 53 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Bladder Cancer Nomograms for Bladder Cancer Shahrokh F. Shariat a, *, Vitaly Margulis
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationDistribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer
Urological Oncology CHUN et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer Felix K.-H. Chun, Georg C.
More informationSystems Pathology in Prostate Cancer
Systems Pathology in Prostate Cancer Policy Number: 2.04.64 Last Review: 8/2014 Origination: 8/2010 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationAccepted for publication 3 January 2005
Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several
More informationUCSF UC San Francisco Previously Published Works
UCSF UC San Francisco Previously Published Works Title Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Permalink https://escholarship.org/uc/item/24j7405c
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationForcasting the Clinical Outcome: Artificial Neural Networks or Multivariate Statistical Models?
17 Forcasting the Clinical Outcome: Artificial Neural Networks or Multivariate Statistical Models? Ahmed Akl and Mohamed A Ghoneim Urology and Nephrology Center, Mansoura Egypt 1. Introduction The field
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationresponse of PCa to testosterone deprivation in the early 1940s, testosterone has been considered as fuel to the fire of PCa.
BJUI BJU INTERNATIONAL Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment Eduardo Garc í a-cruz, Marta Piqueras, Jorge Huguet, Lluis Peri, Laura
More informationUndergrading and Understaging in Patients with Clinically Insignificant Prostate Cancer who Underwent Radical Prostatectomy
Clinical Urology Clinically Insignificant Prostate Cancer International Braz J Urol Vol. 36 (3): 292-299, May - June, 2010 doi: 10.1590/S1677-55382010000300005 Undergrading and Understaging in Patients
More informationAram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*
Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical
More informationInterval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer
DOI 10.1007/s00345-013-1125-0 ORIGINAL ARTICLE Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer D. M. Bolton A. Ta M. Bagnato
More informationFactors Predicting Prostatic Biopsy Gleason Sum Under Grading
Factors Predicting Prostatic Biopsy Gleason Sum Under Grading Danielle A. Stackhouse, Leon Sun, Florian R. Schroeck, Jayakrishnan Jayachandran, Arthur A. Caire, Cyril O. Acholo, Cary N. Robertson, David
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationDevelopment and Internal Validation of a Prostate Health Index Based Nomogram for Predicting Prostate Cancer at Extended Biopsy
Development and Internal Validation of a Prostate Health Index Based Nomogram for Predicting Prostate Cancer at Extended Biopsy Giovanni Lughezzani,*, Massimo Lazzeri, Alessandro Larcher, Giuliana Lista,
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationCorrelation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results
ORIGINAL ARTICLE Correlation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results Gholamreza Pourmand, Shahram Gooran, Seyed Reza Hossieni,
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationApproximately 680,000 men are diagnosed with prostate
Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram E. W. Steyerberg,* M. J. Roobol, M. W. Kattan, T. H. van der Kwast, H. J. de Koning and F. H. Schröder From the
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationPre-treatment risk stratification of prostate cancer patients: A critical review
REVIEW Pre-treatment risk stratification of prostate cancer patients: A critical review George Rodrigues, MD, FRCPC, MSc; * Padraig Warde, FRCPC, MB; Tom Pickles, MD, FRCPC; Juanita Crook, MD, FRCPC; ±
More information